Sprint Bioscience AB (publ) (FRA:5JA1)

Sprint Bioscience AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	126.7	25.06	49.93	29.49	70.64
Cash & Short-Term Investments	126.7	25.06	49.93	29.49	70.64
Cash Growth	405.68%	-49.82%	69.31%	-58.25%	160.92%
Accounts Receivable	-	-	0.8	0.01	0.02
Other Receivables	6.17	12.19	7.14	5.38	5.28
Receivables	6.17	12.19	7.94	5.39	5.29
Total Current Assets	132.87	37.24	57.87	34.88	75.94
Property, Plant & Equipment	3.74	4.72	4.38	2.37	2.99
Long-Term Investments	0.05	0.05	0.05	0.05	0.05
Other Long-Term Assets	0.01	0.05	0.08	0.12	0.16
Total Assets	136.66	42.06	62.38	37.42	79.14
Accounts Payable	4.4	5.44	5.71	3.73	2.92
Accrued Expenses	-	4.7	3.37	4.43	4.54
Current Unearned Revenue	-	11.23	12.32	-	-
Other Current Liabilities	13.08	11.42	13.21	1.07	1.22
Total Current Liabilities	17.48	32.78	34.6	9.23	8.68
Total Liabilities	17.48	32.78	34.6	9.23	8.68
Common Stock	7.07	6.98	6.98	6.98	3.98
Additional Paid-In Capital	291.75	273.67	273.9	273.87	258.97
Retained Earnings	-179.65	-271.38	-253.1	-252.67	-192.5
Shareholders' Equity	119.18	9.27	27.77	28.19	70.45
Total Liabilities & Equity	136.66	42.06	62.38	37.42	79.14
Net Cash (Debt)	126.7	25.06	49.93	29.49	70.64
Net Cash Growth	405.68%	-49.82%	69.31%	-58.25%	313.73%
Net Cash Per Share	1.37	0.36	0.72	0.70	2.45
Filing Date Shares Outstanding	105.52	69.82	69.82	69.8	39.84
Total Common Shares Outstanding	105.52	69.82	69.82	69.8	39.84
Working Capital	115.39	4.46	23.27	25.65	67.25
Book Value Per Share	1.13	0.13	0.40	0.40	1.77
Tangible Book Value	119.18	9.27	27.77	28.19	70.45
Tangible Book Value Per Share	1.13	0.13	0.40	0.40	1.77
Machinery	-	10.96	9.66	7.21	7.21

Source: S&P Global Market Intelligence. Standard template. Financial Sources.